Overview

Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Status:
NOT_YET_RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures. The study consists of four periods: a Screening Period (about 14 days), a Titration Period (8 weeks), a Maintenance Period (4 weeks), and a Follow-Up Period (1 week).
Phase:
PHASE4
Details
Lead Sponsor:
Azurity Pharmaceuticals